COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 45 of 57 for:    CIDP

A Registered Cohort Study of Immune-Mediated Neuropathies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04292834
Recruitment Status : Not yet recruiting
First Posted : March 3, 2020
Last Update Posted : March 10, 2020
Information provided by (Responsible Party):
Ning Wang, MD., PhD., First Affiliated Hospital of Fujian Medical University

Brief Summary:
This study will provide further insights into the natural course of the disease about Immune-Mediated Neuropathies including clinical features,progression, related antibody spectrum and drug treatment effect.

Condition or disease
Chronic Inflammatory Demyelinating Polyneuropathy

Layout table for study information
Study Type : Observational
Estimated Enrollment : 1000 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Registered Cohort Study of Immune-Mediated Neuropathies
Estimated Study Start Date : February 29, 2020
Estimated Primary Completion Date : January 19, 2022
Estimated Study Completion Date : January 19, 2025

Primary Outcome Measures :
  1. The correlation between clinical phenotypes and Serum antibodies [ Time Frame: from date of enrollment until the date of death from any cause,assessed up to 20 years ]
    Different clinical subtypes of GBS and CIDP have different course and prognosis.It may be related to different serum antibodies.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
Patients with GBS,CIDP,MMN who are diagnosied in the First Affiliated Hospital of Fujian Medical Universtiy by two neurolgists

Inclusion Criteria:

- 1. Outpatient or inpatient 2. Meet the diagnostic criteria of various inflammatory peripheral neuropathy. 3. Voluntary participation and informed consent signed by the applicant or his/her family.

4. Age 18 or above

Exclusion Criteria:

  1. Severe complications
  2. Poor prognosis (<1 year survival)
  3. Severe mental disorder and inability to cooperate with the examination.
  4. Age less than 18

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04292834

Layout table for location contacts
Contact: Lin Yi, PhD 86-0591-87982772

Layout table for location information
China, Fujian
Department of Neurology,First Affiliated Hospital of Fujian Medical University
Fuzhou, Fujian, China, 350005
Contact: Wang Ning, PhD    86-0591-87982772   
Principal Investigator: Wang MD Ning, PhD         
Sponsors and Collaborators
Ning Wang, MD., PhD.
Layout table for additonal information
Responsible Party: Ning Wang, MD., PhD., Director, First Affiliated Hospital of Fujian Medical University Identifier: NCT04292834    
Other Study ID Numbers: MRCTA,ECFAH of FMU2019217
First Posted: March 3, 2020    Key Record Dates
Last Update Posted: March 10, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Peripheral Nervous System Diseases
Neuromuscular Diseases
Nervous System Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases